Web Stats Provided By Google Analytics

Saturday, November 18, 2017

FY2017 EPS Estimates for CymaBay Therapeutics Inc. (CBAY) Cut by Analyst

... biopharmaceutical company's stock valued at $100,000 after acquiring an additional 140 shares in the last quarter. Ardsley Advisory Partners lifted its position in shares of CymaBay Therapeutics by 66.2% in the second quarter. Ardsley Advisory ...
http://ift.tt/2itY4zR

No comments:

Post a Comment

Popular Ardsley Roundup Posts